painting for cure, inc.

164-07 27th avenue
flushing, new york 11358

NYS Entity Status
ACTIVE

NYS Filing Date
APRIL 29, 2013

NYS DOS ID#
4395300

County
QUEENS

Jurisdiction
FLORIDA

Registered Agent
NONE

NYS Entity Type
FOREIGN NOT-FOR-PROFIT CORPORATION

Name History
2013 - PAINTING FOR CURE FOUNDATION
2013 - PAINTING FOR CURE, INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Restaurant Review: A New Kind of Sichuan Restaurant for New York
    By PETE WELLS - Tuesday Aug 1, 2017

    In downtown Flushing, Queens, Guan Fu Sichuan shows off the rich variety of flavors beyond the familiar blast of chiles.

    Source: NYT > Home Page
  • Letter of Recommendation: Letter of Recommendation: Karaoke at Home
    By JENNY ZHANG - Friday Jul 7, 2017

    Solo singing as an antidote to bullying, racism and rage.

    Source: NYT > Home Page
  • The Look: New York City Parks in the Summer: Romance, Games and a Performance for a Dying Tree
    By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Sep 2, 2017

    Daniel Arnold spent the last two months photographing parks in all five boroughs. The experience showed him “a very different pulse of the city.”

    Source: NYT > Home Page
  • A New Kind of Classroom: No Grades, No Failing, No Hurry
    By KYLE SPENCER - Friday Aug 11, 2017

    Mastery-based learning allows students to learn at their own pace.

    Source: NYT > Home Page
  • Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
    By Caroline Chen - Tuesday Oct 17, 2017

    Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.

    Source: SFGATE.com: Business and Technology News
  • Budget Bus Lines Flout the Rules With Little Consequence
    By PATRICK McGEEHAN and WINNIE HU - Monday Sep 25, 2017

    Even after deadly crashes like the one in Queens last week, discount bus companies are often able to stay in business and evade serious penalties.

    Source: NYT > Home Page